Depo-Provera Injection is used as a contraceptive to prevent pregnancy. Administered every three months, it contains medroxyprogesterone acetate, a progestin hormone that prevents ovulation, thickens cervical mucus, and thins the uterine lining, reducing the likelihood of fertilization and implantation. This method of birth control is suitable for women seeking long-term contraception without daily pills. Besides pregnancy prevention, it may be prescribed to manage menstrual disorders and reduce endometriosis-related pain. Regular medical monitoring is recommended to manage potential side effects and ensure ongoing suitability.
Depo-Provera Injection by Pfizer is a leading contraceptive solution offering significant convenience and efficacy for women seeking long-term birth control. Each single-dose vial contains 150 mg/mL of medroxyprogesterone acetate, designed for intramuscular administration. With a regimen requiring administration once every three months, Depo-Provera stands as a highly effective and low-maintenance option for those focused on long-term contraceptive needs. Packaged in trays of 25 vials, it is ideal for medical practices and healthcare institutions aiming to provide comprehensive contraceptive care to their patients.
Product Details and Features:
Active Ingredient:Each vial contains 150 mg/mL of medroxyprogesterone acetate, a progestin with potent contraceptive properties.Packaging:Supplied in trays with 25 single-dose vials, facilitating storage and distribution for healthcare providers.Indications:Primarily indicated for the prevention of pregnancy, Depo-Provera is well-suited for individuals preferring an injectable form of contraception.Administration Frequency:Requires administration once every three months, offering highly reliable, uninterrupted protection against pregnancy when used as directed.Quality Assurance:Manufactured by Pfizer, a global leader in pharmaceuticals, ensuring stringent quality control and consistent product performance.
Mechanism of Action:
Depo-Provera works by inhibiting the secretion of gonadotropins from the pituitary gland. This suppression prevents ovulation by halting the maturation of ovarian follicles. Additionally, it induces changes in the cervical mucus, making it thicker and less permeable to sperm. Finally, Depo-Provera alters the endometrial lining to discourage implantation. Together, these effects ensure a highly effective multifunctional approach to preventing pregnancy.
Warnings:
Side Effects:
Common side effects can include:
Serious side effects requiring medical attention include:
Conclusion:
Depo-Provera 150 mg/mL Single-Dose Vials, provided by Pfizer, offer a trusted, highly effective contraceptive option balancing convenience and reliability for long-term birth control. With a proven track record and the backing of Pfizer’s rigorous quality standards, it represents an ideal choice for those seeking dependable contraceptive care. For personalized advice and comprehensive guidance to determine if Depo-Provera is the right choice, always consult with a qualified healthcare professional.
The following information is for guidance only and should not be considered as a diagnosis and is not intended to replace an approved medical treatment. This is not an endorsement of the diagnosis and treatment. This information is provided for general informational purposes only and does not constitute medical advice. The information provided may contain direct or indirect information that is different from the information contained in this e-post. The following information is provided to identify you for purposes of this e-post and does not constitute medical advice. This information is not a substitute for individual medical advice. It is intended to be used for general informational purposes only.
If you are experiencing a periodical periodical amenorrhoea, you should be on the lowest effective dose of the drug, with a maximum daily dose of at least 21 days. Your dose should not exceed a maximum of 21 days, unless directed by your physician. This includes up to three menstrual periods. For the treatment of menstrual periods, the dose may be reduced to 21 days on the first day of your period and 21 days on the second day of your period. The maximum daily dose of the drug should not exceed 12 weeks of continuous daily use of medroxyprogesterone acetate for at least 6 days. If you are in the first four weeks of the first cycle, or the first four weeks of the second cycle, you should be closely monitored by your doctor for the risk of amenorrhoea.
If you are pregnant or plan to become pregnant, you should consult your doctor for a pregnancy test and a possible pregnancy test should be completed by the physician. In the event that you become pregnant during the course of your periodical period, you should immediately discontinue the use of Depo-Provera, unless your doctor directs you to do so. You should not discontinue Depo-Provera without consulting your doctor.
If you are currently taking any other medication, you should always seek advice from your doctor before using this product. This includes non-prescription, over-the-counter, and herbal products that contain prescription or non-prescription medroxyprogesterone acetate. These medications are not intended for human use. In particular, these medications should not be used by women with a history of breast cancer or uterine cancer or those with a history of endometrial hyperplasia or uterine carcinoma.
If you are under 18 years of age, you should use the lowest effective dose of the drug and not exceed 21 days of continuous daily use of the drug, as advised by your doctor.
The maximum daily dose of Depo-Provera, which is also used for the treatment of menstrual periods, is 21 days.
The following information is provided for guidance only and should not be considered as a diagnosis and is not intended to replace an approved medical treatment. This information is provided to provide general guidance on the treatment of vaginal and/or oocyte cancer and is not intended to replace a medical treatment. For a full and complete treatment of vaginal and/or oocyte cancer and the treatment of gynecological cancer, see theDepo-Proverasection of the NIMH-NPS. For the treatment of gynecological cancer, see NIMH-NPS-01-01. For the treatment of uterine cancer, see NIMH-NPS-01-01. For the treatment of endometrial cancer, see NIMH-NPS-01-01.
The following information is provided to provide general information on the safety and efficacy of Depo-Provera and related products. The product information may include a complete list of all the drugs, and a list of all the active drugs and inactive ingredients of the products. The following information is provided to help you choose the most safe and effective Depo-Provera product.
We are a leading manufacturer of Provera (Medroxyprogesterone Acetate) in the United Arab Emirates (UAE). We produce the most popular and highest quality medicine on the UAE market. We have been producing Medroxyprogesterone Acetate since 1979. We are one of the leading UAE pharmaceutical companies producing highly effective and safe medicines for women. Let's find the best deals for you. Get the best price with our online pharmacy.
Eduphine-MUSE is a modern medicine which has gained high attention in the pharmaceutical market since it was first introduced to the market in 1979. It is a highly effective and safe medicine which is manufactured by our modern pharmaceutical company. In this way, it is one of the best medicines on the market for women which has been produced for over 20 years.
Provera (Medroxyprogesterone Acetate) is a widely used medicine in the treatment of conditions such as menstrual disorders, high blood pressure, osteoporosis, depression, sleep disorders, gout, arthritis, diabetes, cancer, and disorders of the menstrual cycle. It is also prescribed for treating conditions such as acne, and acne vulgaris.
The dosage of Provera is determined by the patient's age, weight, menstrual cycle, and disease condition. In the elderly women the dosage can be adjusted according to the body weight. In women with a history of breast cancer, Provera should be given in a dosage of 100-150 mg per day. However, in other cases it may be given in a dosage of 2.5-4 mg per day. In addition, it is advised to discuss with your doctor before starting the treatment with Provera. It is generally safe for use in the treatment of menstrual disorders, high blood pressure, osteoporosis, depression, sleep disorders, gout, arthritis, diabetes, cancer, and disorders of the menstrual cycle.
The most important information regarding the dosage of Provera is contained in the tables. However, it is also advised to discuss with your doctor before starting the treatment with Provera. It is advised to discuss with your doctor about the benefits and risks of the medicine. It is also advised to consult with your doctor before starting the treatment with Provera.
The drug is available in many forms and preparations. The drug should be taken orally, once a day, in the form of a pill. The dosage should be taken according to the patient's weight and age. In addition, in patients with kidney and liver disease, the dosage should be adjusted according to the weight of the patient.
You should follow your doctor's advice and do your own research regarding the dosage of Provera. You should not use it for more than 3 consecutive months without consulting your doctor. It should be used for the shortest time and only after consulting with your doctor.
Appendix - Provera Tablet 1mg (1 tablet) 2.5mg (2 tablets) 3.25mg (3 tablets) 5mg (5 tablets)This medicine is available in many forms and preparations, but it should be used only by the doctors who prescribe it.
Appendix - Provera Tablet 2mg (1 tablet) 3.25mg (2 tablets) 5mg (5 tablets)Depo-Provera (medroxyprogesterone acetate) and other oral medications for the treatment of endometriosis are two popular forms of medicine. Both are FDA-approved medications that are effective for preventing pregnancy and have been linked to an increased risk of complications. However, the use of Depo-Provera (medroxyprogesterone acetate) or Depo-SubQ Provera (medroxyprogesterone acetate) has been associated with serious side effects.
Depo-Provera, or Depo-SubQ Provera, is FDA-approved to treat symptoms of endometriosis, including painful periods, menstrual pain, and infertility. It is also available in both oral and injectable forms. There are a number of side effects associated with Depo-Provera and its use.
Although both are FDA-approved medications, they are not approved for use in the United States. However, Depo-Provera is FDA-approved for use in the states where it was originally developed. While it has been used to treat endometriosis, it was found to be associated with a slight increase in the risk of ovarian cancer. The risk of ovarian cancer is much higher in the long-term use of Depo-Provera. Other side effects include decreased libido, erectile dysfunction, and breast tenderness.
Depo-Provera, commonly referred to as birth control, is a hormone-based contraceptive administered orally, usually in a tablet form. It can be taken with or without food, but you can take the pill at any time of the day.
The Depo-Provera injection is given once daily with or without a progestin. The shot should only be used by women who have a history of or who have certain conditions such as a history of breast cancer, cervical cancer, or endometrial cancer.
It is important to note that Depo-Provera should only be used if you are pregnant or planning to become pregnant. It is also important to note that you should not use any contraception during the course of your pregnancy, and your unborn child may not be able to receive the birth control they need.
The following information is for the Depo-Provera shot. It may not be safe for you to use, as it contains estrogen.
The Therapeutic Goods Administration (TGA) is advising consumers not to purchase or use Australia-certified or registered women's health products (POPs) such as Provera, Femoston, and Mediplan (progesterone-only products).
This article describes current and future available products and services.
Consumer reviews on the Therapeutic Goods Administration (TGA) website indicate that they are not covered by Australian health insurance, that they have been shown to be less effective, and that there is a lack of evidence to support their use. For example, a review for the Therapeutic Goods Administration website states that “We found it to be more effective in treating postmenopausal women with osteoporosis than a placebo, and that the use of medroxyprogesterone is associated with an increased risk of fractures in postmenopausal women.”
Consumer reviews on the Therapeutic Goods Administration website indicate that they are not covered by Australian health insurance, that they have been shown to be less effective, and that there is a lack of evidence to support their use.
Stade de France Pharmacy